ProLynx

ProLynx is a biotechnology company dedicated to developing ultra-long-acting drugs for obesity and related metabolic diseases. The company's proprietary portfolio is based on a proven half-life extension technology, designed to support more stable and long-term treatments while enhancing tolerability and optimized pharmacokinetics.